During the past decade, North Texas Endocrine Center conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 6 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "North Texas Endocrine Center" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Mannkind Corporation" with 2 trials sponsored, "Novartis" with 2 trials sponsored, "Boehringer Ingelheim" with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "North Texas Endocrine Center" #1 collaborator was "Brigham and Women's Hospital" with 1 trials as a collaborator, "Dong-A ST Co., Ltd." with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Mylan GmbH" with 1 trials as a collaborator and "Worldwide Clinical Trials" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "North Texas Endocrine Center" are "Diabetes Mellitus, Type 1" (2 trials), "Diabetes Mellitus, Type 2" (2 trials), "Diabetic Kidney Disease" (2 trials), "Obesity" (2 trials) and "Overweight" (2 trials). Many other conditions were trialed in "North Texas Endocrine Center" in a lesser frequency.

Most popular intervention types in "North Texas Endocrine Center" are "Drug" (15 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Tirzepatide" (3 trials), "Insulin Efsitora Alfa" (2 trials), "vildagliptin" (2 trials) and "70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)" (1 trials). Other intervention names were less common.

The vast majority of trials in "North Texas Endocrine Center" are 16 trials for "All" genders.

Currently, there are NaN active trials in "North Texas Endocrine Center". undefined are not yet recruiting, 2 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in North Texas Endocrine Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in North Texas Endocrine Center, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".